Hämeenlinna Metabolic Syndrome Research Program: Surrogate Indicators for Atherosclerosis

Last updated: May 10, 2010
Sponsor: Central Hospital of Kanta-Hame
Overall Status: Trial Status Unknown

Phase

N/A

Condition

Diabetes Prevention

Heart Attack (Myocardial Infarction)

Hypercholesterolemia

Treatment

N/A

Clinical Study ID

NCT01119404
KHMetS-02-AP
HMS-02
  • Ages 30-65
  • Male
  • Accepts Healthy Volunteers

Study Summary

Mechanisms that link metabolic syndrome to atherosclerosis are incompletely understood. As a part of Hämeenlinna Metabolic Syndrome Research Program (HMS) surrogate indicators for atherosclerosis are studied in 120 men with metabolic syndrome, 120 men with coronary heart disease and 80 physically active controls and in different settings.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Group 1: Metabolic syndrome

  • 120 Finnish men with metabolic syndrome (MetS) defined according to National Cholesterol Education Program (NCEP) Adult Treatment Panel III

  • MetS diagnosed in routine health examination and laboratory tests

  • Age: 30 to 65 years

Group 2: Coronary heart disease (CHD)

  • 120 Finnish men with angiographically proven CHD

  • Age: 30 to 65 years

Group 3: Control

  • 80 Finnish men

  • Exercising physically more than three times a week and more than 30 minutes per exercise on regular basis

  • Never been studied or treated because of cardiovascular disease

  • Age: 30 to 65 years

Study Design

Total Participants: 300
Study Start date:
June 01, 2003
Estimated Completion Date:
December 31, 2014

Study Description

Accumulation of oxidized low-density lipoproteins (LDL) in the intimae of arteries together with risk factors known to enhance atherosclerosis, damage the endothelium of the arterial wall. Dysfunction of the endothelium leads into loss of elasticity of the artery. Surrogate indicators of atherosclerosis might be seen already in the early phase of otherwise subclinical arterial disease.

In this study, we investigate calculated risk of the subjects (SCORE, FINRISK, Framingham score), platelet function and surrogate indicators for atherosclerosis like erectile dysfunction, plasma levels of oxidized LDL, arterial elasticity and biochemical markers for endothelial damage and dysfunction in different settings (case-only and case-control).

Connect with a study center

  • Finnish Red Cross Blood Transfusion Service

    Helsinki, 00310
    Finland

    Completed

  • Mehiläinen Hämeenlinna

    Hämeenlinna, 13100
    Finland

    Site Not Available

  • Central Hospital of Kanta-Häme

    Hämeenlinna, 13530
    Finland

    Active - Recruiting

  • Linnan Klinikka

    Hämeenlinna, 13100
    Finland

    Completed

  • Mehiläinen Hämeenlinna

    Hämeenlinna, 13100
    Finland

    Completed

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.